Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome

Figure 5 Teneligliptin reduced activation of the cardiac NLRP3 inflammasome in the control and diabetic mice. A: NLRP3 and caspase-1 measured by Western blot assays; B: Quantitative analysis of protein expression levels for panel A; C: Production of interleukin-1β as measured by ELISA. ^aP < 0.05 vs control group; ^bP < 0.05 vs streptozotocin group, n = 8. STZ: Streptozotocin.